Login / Signup

Historical Perspective of High-Dose Therapy Followed by Autologous Stem Cell Transplantation in Multiple Myeloma.

Inbar CohenIuliana VaxmanMorie A Gertz
Published in: Acta haematologica (2024)
HDT followed by ASCT remains part of SOC due to its PFS benefit and relatively low toxicity.
Keyphrases
  • stem cell transplantation
  • high dose
  • multiple myeloma
  • low dose
  • cell therapy
  • bone marrow
  • oxidative stress
  • platelet rich plasma
  • stem cells